This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
There were no significant differences in the primary health outcome (16.3% versus 16.0%; p=0.949) or in the incidence of any other complications between the intracoil stent and the PTA groups.
The effectiveness results were presented in full in the main clinical paper (Ansel et al. 2002) .
Clinical conclusions
The results of the trial suggested similar outcomes between the intracoil stent and the PTA groups.
Measure of benefits used in the economic analysis
As the effectiveness results suggested that both techniques had similar outcomes, the analysis should be considered a cost-minimisation analysis.
Direct costs
The direct costs related to health care were included in the analysis. All the cost categories relevant to the perspective adopted seem to have been included. In-hospital, vascular and cardiac catheterisation laboratory (including overhead and depreciation), staff and other hospital costs were identified as important resources categories for the economic evaluation. Detailed information was provided on how each category was derived and computed. Investigators used wellknown bottom-up and top-down techniques to derive the appropriate costs. Hospital charges and cost-to-charge ratios were used to derive ancillary costs. The costs and resource use were reported separately. The hospital unit costs were taken from the finance department at the participating centres. The unit costs were obtained from sources such as the Medicare Fee Schedule (staff costs) and the manufacturer's sales price (stent costs). All costs were expressed in 2002 prices. Discounting was not needed as the time horizon was 9 months.
